New data edge prasugrel closer to Japan filing for coronary syndrome patients undergoing PCI
This article was originally published in Scrip
Executive Summary
Reassured by positive new topline results from a Phase III study in Japan with the oral antiplatelet agent prasugrel, Daiichi Sankyo is aiming to go ahead as planned with a submission in this market for acute coronary syndrome (ACS).